Abion announced on the 7th that it attended BioUSA held in San Diego, USA, from the 3rd to the 6th (local time) to discuss licensing out (LO) and investment attraction with global big pharma companies.
BioUSA, hosted by the Biotechnology Innovation Organization (BIO) in the United States, is considered the world's largest pharmaceutical and biotechnology industry conference. This year, more than 1,500 pharmaceutical and biotech companies and 20,000 industry professionals participated.
At BioUSA, Abion promoted its pipeline research and development achievements and held partnering sessions with global big pharma companies. In particular, it shared clinical result updates of Babamekip (ABN401), which received significant attention at the American Society of Clinical Oncology (ASCO), and provided technical explanations on ABN202 and ABN501.
A company representative said, “There was an influx of inquiries regarding licensing out and investment proposals for Babamekip, which showed higher efficacy compared to global competitive drugs, as well as ABN501, being developed as a first-in-class innovative new drug, and ABN202, an antibody-drug conjugate (ADC) overcoming resistance and limitations.” He added, “It was a meaningful time to explore various business collaboration opportunities in the global market.”
Earlier, from the 31st of last month to the 4th (local time), Abion announced the cutoff results of the Phase 2 clinical trial of Babamekip at ASCO held in Chicago, USA. Babamekip's objective response rate was 54%, significantly surpassing the marketed drugs Tabrecta (48%) and Tepmeco (43%), and the treatment-related adverse events (TRAE) of grade 3 or higher were 10%, overwhelmingly lower than the 28-37.6% of competing drugs. This evaluation increased the possibility of Babamekip becoming the best-in-class new drug in its category.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
